Page 62 - MEMORIA_SEHH-FEHH_2023

MEMORIA ANUAL 2023
SOCIEDAD ESPAÑOLA DE
HEMATOLOGÍA Y HEMOTERAPIA
GESMD
FUNDACIÓN ESPAÑOLA DE
HEMATOLOGÍA Y HEMOTERAPIA
• A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants
With Myelofibrosis and Other Advanced Myeloid Neoplasms. Fase I. Hospital Univer-
sitario de Salamanca, Hospital Universitario Insular de Gran Canarias, Hospital Universi-
tario 12 de Octubre, Hospital Clínico Universitario Virgen de la Arrixaca, Hospital Univer-
sitario de Salamanca.
• A Phase 1b Study of JNJ-75276617 in Combination With AML Directed Therapies for
Participants With Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations.
Fase I. Hospital Clínic de Barcelona, Hospital Universitari Vall d’Hebron, Hospital Univer-
sitario Fundación Jiménez Díaz, Clínica Universidad de Navarra.
• A Phase 1, FIH, Dose Escalation Study of JNJ-74856665 (Dihydroorotate Dehydro-
genase [DHODH] Inhibitor) Alone or in Combination in Participants With AML or MDS.
Fase I. Hospital Clínic de Barcelona, Hospital Universitari Vall d’Hebron, Hospital Univer-
sitario Fundación Jiménez Díaz, Clínica Universidad de Navarra, ICO Durán i Reynals.
• A Phase 3b, Open-label, Single-arm, Rollover Study to Evaluate Long-term Safety in
Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials. Fase
III. Hospital Universitari Vall d’Hebron, Hospital Universitario Central de Asturias.
• A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Ane-
mia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
(MDS). Fase II. Hospital Universitario de Salamanca, Hospital Universitari Vall d’Hebron,
Hospital Universitari i Politècnic La Fe, Hospital Universitario Central de Asturias.
• A Phase IIIb, Open-label, Single Arm Study to Evaluate the Efficacy and Safety of
Luspatercept in Patients With Lower-risk MDS and Ring-sideroblastic Phenotype
(MDS-RS). Fase III. Hospital Universitari i Politècnic La Fe, Hospital Universitario de Sala-
manca, Hospital Universitario Central de Asturias.
• A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD)
Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelo-
dysplastic Syndromes (MDS). Fase I-II. Hospital Universitari Vall d’Hebron, Hospital Uni-
versitari i Politècnic La Fe, Hospital General Universitario Gregorio Marañón, Hospital
Universitario Germans Trias i Pujol.
• A Phase Ib, Multi-arm, Open-label, Study of HDM201 in Combination With MBG453
or Venetoclax in Adult Subjects With Acute Myeloid Leukemia (AML) or High-risk My-
elodysplastic Syndrome (MDS). Fase I. Hospital Universitario 12 de Octubre.
62